Skip to content

Study · Case report or series · n = 1 · 2026

4 results

GLP-1 Receptor Agonist-Associated Slimmer's Palsy: Implications for the Peripheral Nerve Surgeon.

Dhupati P, Kisiel SC, Unadkat K, Noland SS

Annals of plastic surgery1 Jan 2026Cited by 2 (Europe PMC)

PMID41417708 (opens in a new tab)DOI10.1097/sap.0000000000004570 (opens in a new tab)PepBankPUB-41417708
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a nondiabetic patient, acute foot drop developed after 14% total body weight loss over 3-6 months of semaglutide use.

    In plain wordsOne person without diabetes developed foot drop after losing 14% of body weight on semaglutide. A single case cannot show cause.

    Peptide
    Semaglutide
    Outcome
    IncreaseAcute foot drop (common peroneal neuropathy)
    Study

    n = 1

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated · 3-6 monthsAs given in this study (human).

    Source sentences

    Summary
    This case report describes two nondiabetic patients who developed acute foot drop after losing 14% and 18% of their total body weight over 3-6 months of semaglutide and tirzepatide use, respectively.
  2. 02HumanCase report or seriesEfficacy outcome

    In a nondiabetic patient, semaglutide use over 3-6 months was followed by 14% loss of total body weight.

    In plain wordsOne person without diabetes lost 14% of body weight over 3-6 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal body weight loss
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 3-6 monthsAs given in this study (human).

    Measurements

    Total body weight loss
    14%
    semaglutide patient

    Source sentences

    Summary
    This case report describes two nondiabetic patients who developed acute foot drop after losing 14% and 18% of their total body weight over 3-6 months of semaglutide and tirzepatide use, respectively.
  3. 03HumanCase report or seriesSafety outcome

    In a nondiabetic patient, acute foot drop developed after 18% total body weight loss over 3-6 months of tirzepatide use.

    In plain wordsOne person without diabetes developed foot drop after losing 18% of body weight on tirzepatide. A single case cannot show cause.

    Peptide
    Tirzepatide
    Outcome
    IncreaseAcute foot drop (common peroneal neuropathy)
    Study

    n = 1

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated · 3-6 monthsAs given in this study (human).

    Source sentences

    Summary
    This case report describes two nondiabetic patients who developed acute foot drop after losing 14% and 18% of their total body weight over 3-6 months of semaglutide and tirzepatide use, respectively.
  4. 04HumanCase report or seriesEfficacy outcome

    In a nondiabetic patient, tirzepatide use over 3-6 months was followed by 18% loss of total body weight.

    In plain wordsOne person without diabetes lost 18% of body weight over 3-6 months of tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTotal body weight loss
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 3-6 monthsAs given in this study (human).

    Measurements

    Total body weight loss
    18%
    tirzepatide patient

    Source sentences

    Summary
    This case report describes two nondiabetic patients who developed acute foot drop after losing 14% and 18% of their total body weight over 3-6 months of semaglutide and tirzepatide use, respectively.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.